{"entity":{"id":"nct06145048","kind":"trial","name":"Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.","aka":[],"tldr":"A phase 2 trial of Abenacianine run by Vergent Bioscience, Inc., completed.","summary":"Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung. is a phase 2 interventional study registered as NCT06145048 by Vergent Bioscience, Inc., with 89 participants enrolled, started 2023-10-05. Conditions recorded: Lung Cancer and Lung Metastases. Interventions recorded: VGT-309.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06145048","url":"https://clinicaltrials.gov/study/NCT06145048"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["lung-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["abenacianine"],"companies":["vergent-bioscience"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06145048","phase":"2","setting":"A Phase 2, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of VGT-309, a Tumor-Targeted, Activatable Fluorescent Imaging Agent, in Subjects Undergoing Surgery for Cancer in the Lung","sponsor":"Vergent Bioscience, Inc.","enrolled":89,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06145048/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"}],"drug":[{"id":"abenacianine","kind":"drug","name":"Abenacianine","route":"/drugs/abenacianine/"}],"company":[{"id":"vergent-bioscience","kind":"company","name":"Vergent Bioscience","route":"/companies/vergent-bioscience/"}]}}